Inhalerx Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more
Inhalerx Ltd (IRX) - Net Assets
Latest net assets as of June 2025: AU$-877.11K AUD
Based on the latest financial reports, Inhalerx Ltd (IRX) has net assets worth AU$-877.11K AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.44 Million) and total liabilities (AU$2.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-877.11K |
| % of Total Assets | -61.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | -104.83% |
| 10-Year Change | N/A |
| Growth Volatility | 123.45 |
Inhalerx Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Inhalerx Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Inhalerx Ltd (2016–2024)
The table below shows the annual net assets of Inhalerx Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$-63.97K | -109.61% |
| 2023-12-31 | AU$665.47K | -65.03% |
| 2022-12-31 | AU$1.90 Million | -28.94% |
| 2021-12-31 | AU$2.68 Million | +102.27% |
| 2020-12-31 | AU$1.32 Million | +289.29% |
| 2019-12-31 | AU$340.08K | -87.32% |
| 2018-12-31 | AU$2.68 Million | -40.47% |
| 2017-12-31 | AU$4.51 Million | -38.50% |
| 2016-12-31 | AU$7.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inhalerx Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1403017000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$14.53 Million | % |
| Other Comprehensive Income | AU$-212.62K | % |
| Total Equity | AU$-63.97K | 100.00% |
Inhalerx Ltd Competitors by Market Cap
The table below lists competitors of Inhalerx Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Serrano Resources Ltd
PINK:MIRXF
|
$1.39 Million |
|
Key Alliance Group Bhd
KLSE:0036
|
$1.39 Million |
|
Winchester Energy Ltd
AU:WEL
|
$1.39 Million |
|
Khind Holdings Bhd
KLSE:7062
|
$1.39 Million |
|
Glory Forever PCL
BK:GLORY
|
$1.38 Million |
|
Norstar
TA:NSTR
|
$1.38 Million |
|
Argent Minerals Limited
PINK:ARDNF
|
$1.38 Million |
|
Cahaya Bintang Medan Tbk Pt
JK:CBMF
|
$1.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inhalerx Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 665,471 to -63,966, a change of -729,437 (-109.6%).
- Net loss of 1,276,087 reduced equity.
- Share repurchases of 6,350 reduced equity.
- Other comprehensive income increased equity by 28,730.
- Other factors increased equity by 524,270.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-1.28 Million | -1994.95% |
| Share Repurchases | AU$6.35K | -9.93% |
| Other Comprehensive Income | AU$28.73K | +44.91% |
| Other Changes | AU$524.27K | +819.61% |
| Total Change | AU$- | -109.61% |
Book Value vs Market Value Analysis
This analysis compares Inhalerx Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | AU$0.27 | AU$0.03 | x |
| 2017-12-31 | AU$0.06 | AU$0.03 | x |
| 2018-12-31 | AU$0.03 | AU$0.03 | x |
| 2019-12-31 | AU$0.00 | AU$0.03 | x |
| 2020-12-31 | AU$0.01 | AU$0.03 | x |
| 2021-12-31 | AU$0.02 | AU$0.03 | x |
| 2022-12-31 | AU$0.01 | AU$0.03 | x |
| 2023-12-31 | AU$0.00 | AU$0.03 | x |
| 2024-12-31 | AU$0.00 | AU$0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inhalerx Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -380.81%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-139.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -4.76% | -34976.31% | 0.00x | 1.17x | AU$-1.08 Million |
| 2017 | -46.49% | -424.69% | 0.10x | 1.13x | AU$-2.55 Million |
| 2018 | -69.89% | -542.20% | 0.11x | 1.15x | AU$-2.14 Million |
| 2019 | -702.10% | -5124.00% | 0.07x | 1.83x | AU$-2.42 Million |
| 2020 | -76.39% | -1037.33% | 0.05x | 1.44x | AU$-1.14 Million |
| 2021 | -41.49% | -664.15% | 0.06x | 1.09x | AU$-1.38 Million |
| 2022 | -99.95% | -7770.36% | 0.01x | 1.17x | AU$-2.12 Million |
| 2023 | -216.88% | -119.87% | 0.76x | 2.37x | AU$-1.51 Million |
| 2024 | 0.00% | -380.81% | 0.47x | 0.00x | AU$-1.27 Million |
Industry Comparison
This section compares Inhalerx Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inhalerx Ltd (IRX) | AU$-877.11K | -4.76% | N/A | $1.38 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |